Rating innovative therapeutic benefits of medicines licensed in Sweden 1987-1997

International Journal of Pharmaceutical Medicine

Volumn 13, Issue 3, 1999, Pages 123-126

  Rosen A ^a,c   Beermann, B ^b  

^a A Rosén Consulting   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c NONE   (Sweden)

Author keywords

Dosing schedule; Efficacy; Expanded FDA categories; Peri licensing rating of therapeutic benefits; Pharmaceutical innovation; Safety

Indexed keywords

NEW DRUG;

ARTICLE; DRUG ADMINISTRATION; DRUG COST; DRUG DOSE; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; SWEDEN;

EID: 0032800324     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. 1. Food and Drug Administration. Bureau of Drugs staff manual. Guide BD 4820.3, Drug classification. Washington, DC: FDA, 1975.
2. 2. Wardell WM, DiRaddo J, Weintraub M. The measurement of therapeutic value. J Clin Pharmacol 1980; 20:77-90.
3. 3. Avouac B. L'évaluation du service médical rendu, une nécessité pour la Commission deTransparence. Thérapie 1992; 47:9-16.
4. 4. Reekie WD. Medicine prices and innovations: an international survey. The IEA Health and Welfare Unit, London. Choice in Welfare 1996; 30:1-66.
5. 5. Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics 1998; 80:108-118.
6. 6. Schweitzer SO. An international comparison of the approval of new pharmaceuticals. Research program in pharmaceutical economics and policy. USA:UCLA, Oct 1993.